Industry Press Releases

Lonza Expands Support for Researchers with New Endothelial Cell Application Center

Wednesday, Aug 16, 2017
Pressreleases

Today Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers. This new online suite provides scientists with educational materials and product information to assist with vital endothelial cell research. As endothelial cells regulate many homeostatic processes within the body, their dysfunction has important implications for diseases, such as diabetes, cardiovascular disease and cancer. Increasing our understanding of endothelial cells could help researchers to develop more effective drugs to treat these diseases.

Lonza’s easy-to-navigate endothelial cell application center is categorized by research area and can be accessed online anytime and anywhere, making it a handy tool for scientists to use on-demand. The center provides a comprehensive portal of support resources, including technical whitepapers, research publications and product information for applications ranging from inflammation and angiogenesis to cardiovascular disease.

As endothelial cells are particularly hard to co-culture, Lonza’s support center contains materials that provide direction and address questions on setting up more challenging in vitro cultures, such as for blood-brain barrier modeling and tissue engineering. In addition to the resources available in the application center, Lonza also provides custom one-to-one support to further assist scientists with their endothelial cell research.

Lubna Hussain, Senior Global Product Manager for Primary Cells, Lonza, said: “Lonza is committed to supporting the work of scientists and with endothelial cells playing a crucial role in the pathology and treatment of many diseases, we felt it was important to create a centralized portal of materials to assist this research. Resources in our new application center can be viewed online from anywhere and are free to download.”

Lonza offers an extensive range of authenticated, ready-to-use human primary endothelial cells. The portfolio contains more than 30 varieties of human primary endothelial cells from tissue sources ranging from heart, lung, and skin, to the reproductive organs, and includes cells from type I and type II diabetic donors.

To access the endothelial cell application center, please visit http://www.lonza.com/endothelial-cell-application-center. Special terms of use may apply.

About Lonza
Following the closing of the Capsugel acquisition, Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

Lonza Contact Information
Lonza Cologne GmbH
Manager Marketing Communications
Petra Haberkamm
Tel +49 221 991990
petra.haberkamm@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.